{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:40:14Z","timestamp":1769906414350,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001085"],"award-info":[{"award-number":["UL1 TR001085"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Physician prescribing patterns surrounding the use of testosterone therapy (TTh) in men with a history of prostate cancer (CaP) is not well described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To characterize the demographics and usage patterns of testosterone therapy in men with a history of prostate cancer in the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective review using Optum\u2019s De-identified Clinformatics Data Mart database. Administrative diagnosis, procedural, pharmacy, and laboratory codes were used to identify male subjects 40 years and older with prostate cancer treated with surgery or radiation between 2003 and 2018 who went on to receive TTh. Demographic and clinical factors are identified. Temporal trends in TTh usage were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcomes<\/jats:title><jats:p>The main outcomes were rates of testosterone prescriptions in men with treated prostate cancer and associated laboratory values such as Prostate Specific Antigen (PSA) and testosterone levels before TTh.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>126,374 men completed treatment for CaP during the study period (42,515 surgery, 75,186 radiation, 8,673 both). Of these, 3,074 men (2.4%) received testosterone after CaP treatment. Men who received testosterone were younger, more likely to have erectile dysfunction, depressive disorder, and lower pretreatment PSA values compared to men who did not receive. Median PSA levels before TTh initiation were 0 \u2013 0.2 depending on CaP treatment modality and median total testosterone level was &amp;lt;300 ng\/dL. TTh began an average of 1.5 years after radical prostatectomy and 2.6 years after radiation treatment. We observed an increase in TTh after CaP from the beginning of the study period until it peaked in 2013 at 4.9%. After 2013, rates decreased annually until a plateau of approximately 1.8% of men. Approximately a third of men did not have testosterone labs checked before initiation of TTh.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Implications<\/jats:title><jats:p>These findings provide insight into trends in testosterone prescriptions in men after prostate cancer treatment and may aid in clinical decision-making, as well as areas for improvement in cancer survivorship care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Strengths and Limitations<\/jats:title><jats:p>Strengths include the large sample size, length of data coverage, and real-world analysis of testosterone prescribing patterns across the United States. Limitations include the reliance on insurance claims data, the retrospective study design, and lack of additional relevant clinical variables that may impact decision making regarding TTh.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>National trends in testosterone prescriptions for men with treated prostate cancer suggest that many men are treated with TTh after prostate cancer therapy with patterns of indications and monitoring consistent with the general population.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jsxm.2021.06.007","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T07:01:28Z","timestamp":1626937288000},"page":"1346-1353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States"],"prefix":"10.1093","volume":"18","author":[{"given":"Tony","family":"Chen","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine , Stanford, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine , Stanford, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine , Stanford, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J. Urol."},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"183","DOI":"10.21037\/tau.2016.11.16","article-title":"Testosterone deficiency in adults and corresponding treatment patterns across the globe","volume":"6","author":"Anaissie","year":"2017","journal-title":"Transl Androl Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jama.2018.7999","article-title":"Testosterone prescribing in the United States, 2002-2016","volume":"320","author":"Baillargeon","year":"2018","journal-title":"JAMA"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1532-5415.2008.01927.x","article-title":"Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men","volume":"56","author":"Storer","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1210\/jcem-70-3-792","article-title":"Testosterone replacement therapy and sleep-related erections in hypogonadal men","volume":"70","author":"Cunningham","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"921","DOI":"10.21037\/tau.2016.09.08","article-title":"Impact of recent FDA ruling on testosterone replacement therapy (TRT)","volume":"5","author":"Metzger","year":"2016","journal-title":"Transl Androl Urol"},{"key":"2023041407040420500_","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume-title":"Cancer Res","author":"Huggins","year":"1941"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.juro.2010.11.084","article-title":"Testosterone therapy in men with untreated prostate cancer","volume":"185","author":"Morgentaler","year":"2011","journal-title":"J Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.juro.2015.05.084","article-title":"Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer","volume":"194","author":"Pastuszak","year":"2015","journal-title":"J Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11934-018-0812-1","article-title":"The role of testosterone therapy in the setting of prostate cancer","volume":"19","author":"Rodriguez","year":"2018","journal-title":"Curr Urol Rep"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrurol.2014.163","article-title":"The safety of testosterone supplementation therapy in prostate cancer","volume":"11","author":"Dupree","year":"2014","journal-title":"Nat Rev Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.juro.2014.07.123","article-title":"The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy","volume":"193","author":"Klap","year":"2015","journal-title":"J Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bju.13417","article-title":"Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis","volume":"118","author":"Boyle","year":"2016","journal-title":"BJU Int"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamainternmed.2013.6895","article-title":"Trends in androgen prescribing in the United States, 2001 to 2011","volume":"173","author":"Baillargeon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3390\/cancers12082180","article-title":"Characteristics of PSA bounce after radiotherapy for prostate cancer: a meta-analysis","volume":"12","author":"Darwis","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-5347(01)63944-2","article-title":"Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men","volume":"159","author":"Cooper","year":"1998","journal-title":"J Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1111\/jsm.12657","article-title":"Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months","volume":"11","author":"Morgentaler","year":"2014","journal-title":"J Sex Med"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2011.04.065","article-title":"Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory","volume":"186","author":"Khera","year":"2011","journal-title":"J Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4111\/icu.2020.61.4.452","article-title":"Letter to the editor: questioning the evidence behind the saturation model for testosterone replacement therapy in prostate cancer","volume":"61","author":"Morgentaler","year":"2020","journal-title":"Investig Clin Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/01.ju.0000136269.10161.32","article-title":"androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men","volume":"172","author":"Kaufman","year":"2004","journal-title":"J Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1743-6109.2009.01161.x","article-title":"Testosterone replacement therapy following radical prostatectomy","volume":"6","author":"Khera","year":"2009","journal-title":"J Sex Med"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.juro.2013.02.002","article-title":"Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy","volume":"190","author":"Pastuszak","year":"2013","journal-title":"J Urol"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ijir.2012.29","article-title":"Testosterone replacement therapy in the setting of prostate cancer treated with radiation","volume":"25","author":"Pastuszak","year":"2013","journal-title":"Int J Impot Res"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/bju.12668","article-title":"Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer","volume":"114","author":"Balbontin","year":"2014","journal-title":"BJU Int"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cncr.22438","article-title":"Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy","volume":"109","author":"Sarosdy","year":"2007","journal-title":"Cancer"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1464-410X.2008.07882.x","article-title":"Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations","volume":"103","author":"Morales","year":"2009","journal-title":"BJU Int"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1008-682X.160270","article-title":"Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results","volume":"18","author":"Kacker","year":"2016","journal-title":"Asian J Androl"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041407040420500_","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","article-title":"Testosterone therapy in men with prostate cancer","volume":"69","author":"Kaplan","year":"2016","journal-title":"Eur Urol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609521005324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609521005324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/18\/8\/1346\/49876571\/jsm_18_8_1346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/18\/8\/1346\/49876571\/jsm_18_8_1346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T10:10:57Z","timestamp":1699265457000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/18\/8\/1346\/6956149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,7,21]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2021.06.007","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2021.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}